4,925 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Purchased by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,925 shares of the medical research company's stock, valued at approximately $1,590,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. American Century Companies Inc. increased its position in shares of Bio-Rad Laboratories by 14.0% in the first quarter. American Century Companies Inc. now owns 1,286 shares of the medical research company's stock worth $724,000 after acquiring an additional 158 shares in the last quarter. MetLife Investment Management LLC boosted its stake in Bio-Rad Laboratories by 23.0% during the 1st quarter. MetLife Investment Management LLC now owns 5,872 shares of the medical research company's stock valued at $3,307,000 after acquiring an additional 1,097 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Bio-Rad Laboratories by 6.6% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 2,891 shares of the medical research company's stock valued at $1,628,000 after acquiring an additional 179 shares during the last quarter. Raymond James Trust N.A. raised its holdings in shares of Bio-Rad Laboratories by 5.5% during the first quarter. Raymond James Trust N.A. now owns 501 shares of the medical research company's stock worth $283,000 after purchasing an additional 26 shares during the period. Finally, Allianz Asset Management GmbH raised its holdings in shares of Bio-Rad Laboratories by 11.9% during the first quarter. Allianz Asset Management GmbH now owns 65,094 shares of the medical research company's stock worth $36,663,000 after purchasing an additional 6,936 shares during the period. Hedge funds and other institutional investors own 65.24% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BIO shares. UBS Group increased their price objective on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a "buy" rating in a report on Friday, February 16th. Citigroup lowered shares of Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $400.00 to $365.00 in a research report on Wednesday, April 3rd. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, April 5th. Finally, Royal Bank of Canada reduced their price objective on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an "outperform" rating for the company in a research report on Friday, February 16th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $468.00.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock traded down $11.42 during midday trading on Friday, hitting $300.45. The company had a trading volume of 251,160 shares, compared to its average volume of 170,686. The business's 50 day simple moving average is $333.37 and its two-hundred day simple moving average is $322.28. The stock has a market cap of $8.57 billion, a PE ratio of -13.98 and a beta of 0.87. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.83 and a quick ratio of 4.34. Bio-Rad Laboratories, Inc. has a 1-year low of $261.59 and a 1-year high of $494.05.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.17. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The firm had revenue of $681.18 million for the quarter, compared to the consensus estimate of $685.00 million. During the same quarter in the previous year, the company earned $3.31 earnings per share. The business's revenue was down 6.7% compared to the same quarter last year. As a group, equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current fiscal year.

Insider Buying and Selling

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of the company's stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the transaction, the executive vice president now directly owns 6,942 shares in the company, valued at approximately $2,332,512. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 17.06% of the stock is owned by corporate insiders.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.